Johnson & Johnson (JNJ) Stock Price, Quote & News

Company Profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospit...

Industry: Drug Manufacturers - General

Sector: Healthcare

Phone: 732 524 0400

Website: www.jnj.com

Address:

One Johnson & Johnson Plaza, New Brunswick, United States

TechTraderGrok Apr. 7 at 9:04 PM

Sold $JNJ at $238.8 (-0.5%). From Grok: "Exiting our long from 239.93 on 3/25 as JNJ shows short-term weakness and distribution after failing to hold gains toward 248 resistance, with earnings risk in a week. " https://www.techtrader.ai/grokwall/?post=17615&utm_source=dlvr.it&utm_medium=stocktwits

0 · Reply

DragonAlgo Apr. 7 at 7:02 PM

🐉 $JNJ CALL — DragonAlgo® Signal Contract: JNJ CALL Expiry: 2026-04-10 | Strike: $237.50 | Type: CALL Option Plan (premium): Entry: $3.73 Stop: $2.68 TP1: $4.84 TP2: $6.33 TP3: $8.94 Volatility regime is active. 🔗 https://dragonalgo.com

0 · Reply

GordoHLYK13 Apr. 7 at 5:48 PM

$CUE $JNJ you can spin it however you want, but facts don’t lie — Cue just secured a $7.5M milestone payment from Boehringer Ingelheim, proving real partnership traction and ongoing value creation. Today’s R&D presentation wasn’t hype — it reinforced progress on CUE-401, a next-gen platform in a massive unmet market, now under new interim CEO leadership focused on execution from $JNJ . Call it what you want… but partnerships, funding, and pipeline progress don’t scream “failure” — they scream momentum. 🚀

0 · Reply

GordoHLYK13 Apr. 7 at 4:27 PM

$CUE $JNJ Buddy You’re calling it failure, but ignoring what actually matters. • **Merck & Co. didn’t walk away from broken science — they walked after getting what they needed: 👉 human validation of the platform That’s exactly what CUE used to pivot. • CUE-101 = oncology signal • Now → CUE-401 = autoimmune (bigger, chronic market) That’s not “starting from scratch” — that’s evolving the platform where the ROI is higher ⸻ • Interim CEO with Johnson & Johnson background 👉 That’s not desperation — that’s Big Pharma execution stepping in ⸻ • “Delisting in 2 weeks” is just wrong Compliance processes take time, extensions exist, and companies don’t host R&D Days + initiate INDs if they’re folding ⸻ 🔥 Old asset didn’t pan out commercially — happens all the time in biotech. Platform got validated — that’s what survives. Now they’re: 👉 Advancing CUE-401 👉 Entering autoimmune 👉 Moving toward IND That’s not a company dying — that’s one repositioning before the next phase.

1 · Reply

GordoHLYK13 Apr. 7 at 4:21 PM

$CUE Shortie @SirDuncan You’re mixing old $CUE with new $CUE. • CEO with Johnson & Johnson background stepping in = execution, not a red flag • IND “not guaranteed” — sure, but trials don’t take until 2027 if cleared… it’s months, not years • CUE-101 didn’t “fail” — it validated the platform in humans Now they’re pivoting to CUE-401 (autoimmune = bigger market) 👉 This isn’t the same company you’re criticizing. $JNJ

1 · Reply

LightCrocodile Apr. 7 at 4:19 PM

$JNJ defensive slow mover not much momentum

0 · Reply

GordoHLYK13 Apr. 7 at 4:02 PM

$CUE $CUE just flipped the switch today. CUE-401 showing immune reset potential… Doctors backing the science… CEO with Big Pharma pedigree… And now: 👉 IND officially being initiated = human trials next That’s the line between a $30M biotech and a re-rated clinical-stage company. ➡️ Market still pricing preclinical risk… while the company is stepping into human trials + autoimmune expansion That’s how billion-dollar runs quietly begin. $JNJ

1 · Reply

twincam Apr. 7 at 12:59 PM

$MPLT With patent cliffs looming, $MPLT looks like prime M&A bait. Circuit-targeted CNS drugs + Q3 ’26 readouts in schizo & autism. Ready to take on BMS? Watch $JNJ, $SNY, $LLY. $MPLT”

0 · Reply

GordoHLYK13 Apr. 7 at 12:21 PM

$CUE The $7.5 Million Cash Injection (Confirmed Today) An SEC filing and press release went live early this morning confirming that Boehringer Ingelheim has approved the first compound for lead optimization. • The Payout: CUE will receive a $7.5 million milestone payment in May. • Why it matters: For a company with a tiny market cap (~$25M) that has been burning cash, this is "free" money that doesn't dilute existing shareholders. It essentially validates their tech platform with a major big-pharma partner. 2. The 10:00 AM R&D Day (The "Setup") Traders are likely combining the $7.5M "win" with the upcoming Virtual R&D Day at 10:00 AM ET. • The market often sees a "milestone payment" right before an R&D day as a signal that the company is about to present very strong data for their lead asset, CUE-401. • High-profile medical experts from St. Louis University and UMass are presenting, which adds "institutional" weight to the hype. $JNJ $PFE $ABBV

0 · Reply

EthelBurkhardt272 Apr. 7 at 12:18 PM

$JNJ $UNH defensive money still active here. not exciting, but very consistent buying behavior

0 · Reply

Johnson & Johnson Advances Pulsed Field Ablation Portfolio with the Launch of VARIPULSE Pro in Europe

Mar 30, 2026, 9:14 AM EDT - 8 days ago

Royalty Pharma and J&J partner to develop autoimmune treatment

RPRX

Mar 28, 2026, 10:00 AM EDT - 10 days ago

ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis

Mar 27, 2026, 4:46 PM EDT - 11 days ago

Johnson & Johnson (JNJ) Price Forecast: Bull Flag Signals Strength

Mar 27, 2026, 6:31 AM EDT - 11 days ago

Johnson & Johnson's DARZALEX® (daratumumab) becomes the first oncology injectable approved for administration by patients or caregivers

Mar 19, 2026, 1:00 PM EDT - 19 days ago

The Big 3: ORCL, JNJ, SBUX

ORCL SBUX

Mar 19, 2026, 9:35 AM EDT - 19 days ago

JNJ Stock's Re-Rating: When The Market Finally Sees A Different Company

Mar 18, 2026, 2:23 PM EDT - 20 days ago

TrumpRx lists many medicines at prices higher than paid in UK

ABBV AMGN AZN BMY GILD GSK LLY

Mar 18, 2026, 1:17 PM EDT - 20 days ago

FDA approves psoriasis pill from J&J that rivals shots Tremfya, Skyrizi

Mar 18, 2026, 8:31 AM EDT - 20 days ago

US FDA approves J&J's oral psoriasis pill

Mar 18, 2026, 7:49 AM EDT - 20 days ago

FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide

Mar 16, 2026, 11:00 AM EDT - 22 days ago

Johnson & Johnson Drives Innovation in Pulsed Field Ablation with Peru Launch

Mar 13, 2026, 12:35 PM EDT - 25 days ago

Johnson & Johnson highlights promising first-in-human Erda-iDRS (formerly TAR-210) results in intermediate-risk non-muscle-invasive bladder cancer

Mar 12, 2026, 8:00 AM EDT - 26 days ago

Johnson & Johnson Announces FDA Approval of TECNIS PureSee Intraocular Lens, a Breakthrough Solution for U.S. Cataract Patients

$Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line$

Mar 5, 2026, 3:55 PM EST - 4 weeks ago

Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line

Mar 5, 2026, 2:21 PM EST - 4 weeks ago

US FDA approves JNJ's blood cancer drug

Mar 4, 2026, 6:07 PM EST - 4 weeks ago

Johnson & Johnson launches website for direct-to-consumer sales

Mar 3, 2026, 8:03 AM EST - 5 weeks ago

Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)

Mar 2, 2026, 4:30 PM EST - 5 weeks ago

Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Feb 26, 2026, 2:30 PM EST - 5 weeks ago

Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

Feb 24, 2026, 4:03 PM EST - 6 weeks ago

Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

Feb 23, 2026, 11:35 AM EST - 6 weeks ago

Does JNJ Stock Still Offer Value?

Feb 23, 2026, 10:43 AM EST - 6 weeks ago

Bayer files lawsuit against Johnson & Johnson, Janssen Biotech

Feb 23, 2026, 10:28 AM EST - 6 weeks ago

Bayer Alleges J&J's Claims Regarding NUBEQA® are Deeply Flawed and Intentionally Aimed at Boosting Sales of J&J's ERLEADA

Feb 21, 2026, 8:00 AM EST - 6 weeks ago

TREMFYA® (guselkumab) long-term data show sustained clinical and endoscopic remission in ulcerative colitis through 3 years

Feb 19, 2026, 5:00 PM EST - 6 weeks ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) plus immunotherapy shows strong clinical benefit with 56 percent overall response rate in first-line recurrent or metastatic head and neck cancer

Feb 19, 2026, 2:34 PM EST - 6 weeks ago

Johnson & Johnson explores $20 billion sale of an orthopedics unit, Bloomberg News reports

Feb 19, 2026, 2:11 PM EST - 6 weeks ago

Johnson & Johnson to invest $1B in Pennsylvania manufacturing facility

Feb 18, 2026, 10:44 AM EST - 6 weeks ago

Johnson & Johnson to Invest More Than $1 Billion in Pennsylvania Cell Therapy Factory

Feb 18, 2026, 10:17 AM EST - 6 weeks ago

J&J to invest $1 billion in new Pennsylvania plant amid US manufacturing push

Feb 18, 2026, 10:15 AM EST - 6 weeks ago

Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania

Feb 18, 2026, 7:30 AM EST - 6 weeks ago

RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Breakthrough Therapy Designation for patients with advanced head and neck cancer

Feb 17, 2026, 8:00 AM EST - 7 weeks ago

FDA approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) as the only EGFR-targeted therapy that can be administered once a month

Feb 13, 2026, 4:19 PM EST - 7 weeks ago

Johnson & Johnson found liable for cancer in latest talc trial, ordered to pay $250K

Feb 13, 2026, 4:18 PM EST - 7 weeks ago

Philadelphia Jury Returns $250,000 Verdict Against J&J in Latest Baby Powder-Ovarian Cancer Trial

Feb 13, 2026, 2:43 PM EST - 7 weeks ago

Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial

Feb 13, 2026, 7:00 AM EST - 7 weeks ago

After A 55% Surge, Is JNJ Stock Still A Buy?

Feb 11, 2026, 2:23 PM EST - 7 weeks ago

NIH Stops Johnson & Johnson's Blood Thinner Drug Arm In Stroke Trial After Safety Review

Feb 9, 2026, 4:16 PM EST - 2 months ago

Johnson & Johnson to Participate in the Barclays 28th Annual Global Healthcare Conference

Feb 6, 2026, 7:00 PM EST - 2 months ago

Johnson & Johnson Presents Early Outcomes from the OMNY-AF Pilot Study at 2026 AF Symposium

Feb 5, 2026, 1:00 PM EST - 2 months ago

The Big 3: JNJ, XOM, KO

XOM KO

Feb 4, 2026, 1:37 PM EST - 2 months ago

These hot S&P 500 stocks show where investors are heading as they run away from tech

FDX NOC NSC RTX WMT XOM

Feb 3, 2026, 8:47 AM EST - 2 months ago

What's Behind The 50% Surge In JNJ Stock?

Feb 3, 2026, 3:00 AM EST - 2 months ago

Johnson & Johnson Launches the First and Only Daily Disposable Multifocal Toric Contact Lens for Astigmatic Patients with Presbyopia in United Kingdom and Ireland

Feb 2, 2026, 4:34 PM EST - 2 months ago

Johnson & Johnson to Participate in the TD Cowen 46th Annual Health Care Conference

Jan 30, 2026, 7:19 AM EST - 2 months ago

Johnson & Johnson receives CHMP positive opinion for AKEEGA® (niraparib and abiraterone acetate dual action tablet) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with BRCA1/2 mutations

Jan 29, 2026, 6:32 PM EST - 2 months ago

US judge tosses lawsuit accusing J&J of fraud over talc bankruptcy strategy

Jan 29, 2026, 12:42 PM EST - 2 months ago

This Winning Fund Pro Likes J&J, Lowe's, and Utility Stocks

LOW

Jan 27, 2026, 3:49 PM EST - 2 months ago

DARZALEX FASPRO®-based quadruplet regimen approved in the U.S. for newly diagnosed patients with multiple myeloma who are transplant ineligible

Jan 27, 2026, 8:00 AM EST - 2 months ago

Johnson & Johnson Marks $100 Million of MedTech Products Donated Since 2020 to Help People Live, See and Smile

TechTraderGrok Apr. 7 at 9:04 PM

0 · Reply

DragonAlgo Apr. 7 at 7:02 PM

0 · Reply

GordoHLYK13 Apr. 7 at 5:48 PM

0 · Reply

GordoHLYK13 Apr. 7 at 4:27 PM

1 · Reply

GordoHLYK13 Apr. 7 at 4:21 PM

1 · Reply

LightCrocodile Apr. 7 at 4:19 PM

$JNJ defensive slow mover not much momentum

0 · Reply

GordoHLYK13 Apr. 7 at 4:02 PM

1 · Reply

twincam Apr. 7 at 12:59 PM

$MPLT With patent cliffs looming, $MPLT looks like prime M&A bait. Circuit-targeted CNS drugs + Q3 ’26 readouts in schizo & autism. Ready to take on BMS? Watch $JNJ, $SNY, $LLY. $MPLT”

0 · Reply

GordoHLYK13 Apr. 7 at 12:21 PM

0 · Reply

EthelBurkhardt272 Apr. 7 at 12:18 PM

$JNJ $UNH defensive money still active here. not exciting, but very consistent buying behavior

0 · Reply

ElliottwaveForecast Apr. 7 at 11:05 AM

$JNJ favors rally towards 256.3 or higher to extend January-2025 bullilsh sequence It favors wave ((5)), while dips remain above 232.24 low to extend daily rally. Further upside will confirm above 3.02.2026 high to rule out the double correction in ((4)) if breaks below 232.24. #Elliottwave #JNJ

0 · Reply

DonCorleone77 Apr. 7 at 10:52 AM

$JNJ Johnson & Johnson price target raised to $285 from $274 at Citi Citi raised the firm's price target on Johnson & Johnson to $285 from $274 and keeps a Buy rating on the shares. The firm adjusted targets in the medical technology group as part of a Q1 preview. The "walls of worry are high" into the earnings reports with the sector undergoing significant multiple compression, the analyst tells investors in a research note. Citi removed iRhythm and Medtronic as top picks. The firm's top picks are now Edwards Lifesciences and Intuitive Surgical.

0 · Reply

The__short_squeezer Apr. 7 at 8:25 AM

$WMT $ORCL $MU $SNDK $JNJ My fellow Americans who support the Democratic Party, I don't understand you. You support individual freedoms. How come you don't support the overthrow of the fanatical regime in Iran that oppresses the population and murders its people en masse when they take to the streets to demand freedom? How come it doesn't bother you that this regime murdered in two days a number similar to the number that Israel killed in two years (of course, there Israel avoided harming the civilian population as much as it could, but it's very difficult when terrorists fire rockets from a concentration of civilian population towards another civilian population. Eliminating only those terrorists and not eliminating them is out of the question, because why would Israel prefer the hostile population of Gaza over its own population?) Why did you demonstrate for terrorist Gaza (because the population supports Hamas) and not for the liberal citizens of Iran? Strange, isn't it...?

4 · Reply

DragonAlgo Apr. 7 at 12:48 AM

🐉 $JNJ PUT — DragonAlgo® Signal Contract: JNJ PUT Expiry: 2026-04-17 | Strike: $240.00 | Type: PUT Option Plan (premium): Entry: $4.85 Stop: $3.49 TP1: $6.30 TP2: $8.24 TP3: $11.64 🔗 https://dragonalgo.com

0 · Reply

Quantumup Apr. 6 at 8:19 PM

Clear Street⬆️ $PTGX's PT to $116 from $104 and reiterated at a Buy rating. $JNJ $ABBV BMY ALMS ABVX TAK Clear Street said in its note: We come away incrementally more constructive following our post-AAD management meeting and raise our PT to $116 from $104, with ICOTYDE further de-risking as a differentiated oral IL-23 and emerging as a potential best-in-class option in chronic indications. Its clean label (no TB test), placebo-like safety, and SKYRIZI-like, highly competitive efficacy (vs. SOTYKTU and potentially STELARA) can credibly position ICOTYDE as a preferred choice for long-term (maintenance) use, where oral convenience should further accelerate adoption. Accordingly, we increase our PsO peak penetration assumption to 18% from 15%, driving our PT revision.

0 · Reply

Suite510 Apr. 6 at 6:25 PM

$JNJ $KVUE $SPX tic tock tic tock take $240 and exit stage left 😂

0 · Reply

trenddetector Apr. 6 at 4:01 PM

$JNJ Share this site with anyone that has cancer, or has a friend or family member with cancer, and is searching for options. A great resource for those confused about approved treatments and trials that are enrolling. https://nimble-frangollo-81ff5e.netlify.app/#

0 · Reply

SparkyReturns Apr. 6 at 3:45 PM

$ICU Up 10% so far today. Market Cap still only 17 Million. TAM in the tens of Billions. [Read that again} For a device with 6 BDDs, multiple grants, becoming standard of care, and a TAM in the tens of BILLIONS. Somebody pinch me to make sure I'm not dreaming. $NVO $JNJ $ABBV $AZN

2 · Reply

EthelBurkhardt272 Apr. 6 at 3:36 PM

$JNJ classic place people hide when they still want exposure but less stress

0 · Reply

Quantumup Apr. 6 at 11:17 AM

Guggenheim⬆️ $ORKA's PT to $125 from $60 and reiterated at Buy. $ABBV $JNJ PTGX UCBJY Here's what Guggenheim had to say in its note: https://x.com/Quantumup1/status/2041111882489106643?s=20

0 · Reply

papasANDbeer Apr. 6 at 6:02 AM

$SPY $JNJ wuuuuuhat? $DJT

0 · Reply

The__short_squeezer Apr. 5 at 5:57 PM

$WMT $ORCL $MU $SNDK $JNJ

0 · Reply

Market Cap	585.39B
Revenue (ttm)	94.19B
Net Income (ttm)	26.80B
EPS (ttm)	N/A
PE Ratio	22.60
Forward PE	21.15
Profit Margin	28.46%
Debt to Equity Ratio	0.48

Volume	6,228,399
Avg Vol	8,419,548
Day's Range	N/A - N/A
Shares Out	2.41B
Stochastic %K	58%
Beta	0.34
Analysts	Strong Sell
Price Target	$243.16